Personalis 2026 guidance for $78–80M revenue and 15–20% gross margin
Personalis reports Q4 and full-year 2025 results and issues 2026 guidance for $78–80M revenue and 15–20% gross margin
- Highlighted new Medicare coverage for breast and lung cancer MRD tests during the Q4 and full-year 2025 results.
- Reported a year-end 2025 cash balance of approximately $240M, indicating cash resources at that time.
- 2026 outlook also includes an expected net loss of approximately $105M, with revenue of $78–80M and 15–20% gross margin.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.